Preliminary safety, efficacy, and PK/PD characterization from GARNET, a phase I clinical trial of the anti-PD-1 monoclonal antibody, TSR-042, in patients with recurrent or advanced MSI-H endometrial cancer.

Trial of the Anti-PD-1 Monoclonal Antibody, TSR-042, in Patients with Recurrent or Advanced MSI-H Endometrial Cancer Ana Oaknin,1 Susan L. Ellard,2 Charles Leath, III,3 Victor Moreno,4 Rebecca Kristeleit,5 Wei Guo,6 Sharon Lu,6 David Jenkins,6 Kristen McEachern,6 Kai Yu Jen,6 Steven Dunlap,6 Ellie Im,6 Lucy Gilbert7 1Vall d ́Hebron University Hospital, Vall d ́Hebrón Institute of Oncology (VHIO), Barcelona, Spain; 2British Columbia Cancer Agency and University of British Columbia, Vancouver, BC, Canada; 3University of Alabama at Birmingham, Birmingham, AL, USA; 4START MADRID-FJD, Hospital Fundación Jiménez Díaz, Medical Oncology Department, Madrid, Spain; 5University College London, UCL Cancer Institute, Department of Oncology, London, United Kingdom; 6TESARO, Inc., Waltham, MA, USA; 7Research Institute-McGill University Health Centre, Montreal, QC, Canada